妊娠期HIV阳性女性达芦那韦/利托那韦给药方案的半机制药代动力学模型评估
该研究基于85名女性的数据建立群体药代动力学模型,模拟妊娠晚期标准达芦那韦/利托那韦给药方案的总和游离药物暴露。结果显示标准q12h方案的治疗暴露概率(游离)为99%,高于q24h方案的94%,提示妊娠期首选达芦那韦/利托那韦600/100 mg q12h。
要点
- 妊娠期标准q12h方案游离达芦那韦治疗暴露概率为99%,高于q24h的94%。
- 妊娠期总达芦那韦暴露较产后降低24%(q24h)和23%(q12h)。
- 妊娠期首选达芦那韦/利托那韦600/100 mg q12h,除非依从性问题需q24h给药。
核心结论
- 标准q12h方案在妊娠期提供最大且最高的治疗暴露率,应作为首选方案。
- 除非依从性问题决定使用q24h,否则妊娠期推荐达芦那韦/利托那韦600/100 mg q12h。
研究设计与样本
- 基于85名女性的数据进行的群体药代动力学分析,模拟妊娠晚期总与游离达芦那韦的AUC0-τ和Ctrough。
主要发现
- 模拟预测妊娠期总达芦那韦AUC0-τ在标准q24h和q12h方案下分别降低24%和23%。
- 游离达芦那韦AUC0-τ在标准q24h和q12h方案下分别较产后降低5%和8%。
- 妊娠期游离达芦那韦治疗暴露概率:标准q12h方案为99%,q24h方案为94%。
关键数值与推荐
- 妊娠期标准q12h方案游离达芦那韦治疗暴露概率为99%,q24h方案为94%。
- 妊娠期总达芦那韦AUC0-τ降低:q24h方案24%,q12h方案23%。
- 游离达芦那韦AUC0-τ降低:q24h方案5%,q12h方案8%。
临床怎么用
- 妊娠期HIV阳性女性应优先选择达芦那韦/利托那韦600/100 mg q12h方案。
- 仅在存在依从性问题时考虑q24h给药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Darunavir 800 mg once (q24h) or 600 mg twice (q12h) daily combined with low-dose ritonavir is used to treat HIV-positive pregnant women. Decreased total darunavir exposure (17%-50%) has been reported during pregnancy, but limited data on unbound exposure are available. OBJECTIVES: To evaluate total and unbound darunavir exposures following standard darunavir/ritonavir dosing and to explore the value of potential optimized darunavir/ritonavir dosing regimens for HIV-positive pregnant women. PATIENTS AND METHODS: A population pharmacokinetic analysis was conducted based on data from 85 women. The final model was used to simulate total and unbound darunavir AUC0-τ and Ctrough during the third trimester of pregnancy, as well as to assess the probability of therapeutic exposure. RESULTS: Simulations predicted that total darunavir exposure (AUC0-τ) was 24% and 23% lower in pregnancy for standard q24h and q12h dosing, respectively. Unbound darunavir AUC0-τ was 5% and 8% lower compared with post-partum for standard q24h and q12h dosing, respectively. The probability of therapeutic exposure (unbound) during pregnancy was higher for standard q12h dosing (99%) than for q24h dosing (94%). CONCLUSIONS: The standard q12h regimen resulted in maximal and higher rates of therapeutic exposure compared with standard q24h dosing. Darunavir/ritonavir 600/100 mg q12h should therefore be the preferred regimen during pregnancy unless (adherence) issues dictate q24h dosing. The value of alternative dosing regimens seems limited.
引用
- Schalkwijk S, Ter Heine R, Colbers A, et al. Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. J Antimicrob Chemother. 2019. PMID: 30715324. doi:10.1093/jac/dky567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。